MPLT
NASDAQMapLight Therapeutics Inc.
Price$28.07+10.08 (+56.03%)
2026-03-042026-06-05
News · 26 weeks73-87%
2025-12-142026-06-07
Mix4790d
- Insider20(43%)
- SEC Filings17(36%)
- Analyst6(13%)
- Other4(9%)
Latest news
25 items- ANALYSTUBS initiated coverage on MapLight Therapeutics with a new price targetUBS initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $48.00
- ANALYSTCraig Hallum initiated coverage on MapLight Therapeutics with a new price targetCraig Hallum initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $43.00
- INSIDERChief Executive Officer Kroeger Christopher A. sold $3,215,000 worth of Voting Common Stock (118,235 units at $27.19) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 1,394,094 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 10-Q filed by MapLight Therapeutics Inc.10-Q - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECMapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
- PRMapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateEnrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004's Phase 2 IRIS trial in autism spectrum disorder, with topline results expected by mid-August 2026Enrollment ongoing in ML-007C-MA's Phase 2 VISTA trial in Alzheimer's disease psychosis, with topline results expected in the second half of 2027Ended the quarter with $395.2 million in cash, cash equivalents and investments, which is expected to fund operations through 2027 SAN FRANCISCO and BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on im
- INSIDERChief Medical Officer Foff Erin Pennock sold $126,640 worth of Voting Common Stock (4,438 units at $28.54) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 346,059 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERGeneral Counsel Hanson Kristopher sold $419,263 worth of Voting Common Stock (13,917 units at $30.13) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 162,331 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Executive Officer Kroeger Christopher A. sold $1,949,634 worth of Voting Common Stock (68,491 units at $28.47) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,512,329 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Scientific Officer Lillie James Woodruff sold $20,390 worth of Voting Common Stock (721 units at $28.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.30% to 242,729 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- PRMapLight Therapeutics to Participate in Upcoming Investor ConferencesSAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences: Event: 2026 RBCCM Global Healthcare Conference (New York, NY)Date: Tuesday, May 19thFormat: Presenting and hosting 1x1 meetings Event: 2026 Jefferies Global Healthcare Conference (New York, NY)Date: Wednesday, June 3rdFormat: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & Presentations" page on the Investor section of the company's website at https://ir.maplightrx.c
- INSIDERChief Executive Officer Kroeger Christopher A. sold $1,412,235 worth of Voting Common Stock (49,744 units at $28.39) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,580,820 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERGeneral Counsel Hanson Kristopher sold $388,177 worth of Voting Common Stock (13,917 units at $27.89) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 176,248 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Financial Officer Setia Vishwas sold $1,024,719 worth of Voting Common Stock (36,371 units at $28.17) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 356,256 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Medical Officer Foff Erin Pennock sold $1,427,594 worth of Voting Common Stock (50,280 units at $28.39) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 350,497 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Scientific Officer Lillie James Woodruff sold $1,468,251 worth of Voting Common Stock (51,707 units at $28.40) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 243,450 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- ANALYSTH.C. Wainwright initiated coverage on MapLight Therapeutics with a new price targetH.C. Wainwright initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $45.00
- PRMapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline ResultsEnrollment completed in ML-007C-MA's ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004's IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2 trials expected by mid-August 2026 SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The Company also announced completion of the final patient visit in its Phase 2 IRIS tri
- INSIDERChief Discovery Officer Kreitzer Anatol sold $1,347,066 worth of Voting Common Stock (45,422 units at $29.66) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 211,190 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERCAAO and PAO Gillis Jonathan sold $2,087,687 worth of Voting Common Stock (69,835 units at $29.89) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 181,219 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 8-K filed by MapLight Therapeutics Inc.8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECSEC Form DEFA14A filed by MapLight Therapeutics Inc.DEFA14A - MapLight Therapeutics, Inc. (0001770069) (Filer)
MPLT FAQ
6 questionsWhere does MPLT stock trade?
MapLight Therapeutics Inc. (MPLT) is listed on NASDAQ.What sector and industry is MPLT in?
MapLight Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MapLight Therapeutics Inc. go public?
MapLight Therapeutics Inc. (MPLT) completed its IPO in 2025.What are analysts saying about MPLT?
MapLight Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $4800.00 price target on 2026-05-27. Recent price targets range from $2800.00 to $4800.00.What companies are similar to MPLT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MPLT side-by-side with any of them on Quantisnow.How can I track MPLT on Quantisnow?
Quantisnow aggregates MapLight Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MPLT to receive live email and push alerts on every new disclosure.